Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Gesynta Pharma AB
AB
Active
Org 5591036628
Wallingatan 24, 111 24
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2017 · 9 years old
4 employees
Overvåg
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Gesynta Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
-67M
2025
EBITDA
SEK millions
0M
-28M
-55M
-83M
-110M
-80M
2021
-80M
0%
2022
-20M
+75%
2023
-15M
+25%
2024
-88M
-487%
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
0
0
47
0
−66 810
Staff expenses
—
—
—
−6 007
−12 933
EBITDA
−79 835
−80 096
−20 354
−15 487
−88 123
Depreciation & amort.
−53
−53
−53
−34
−20
EBIT
−79 888
−80 149
−20 407
−15 521
−88 143
Net financials
198
296
480
296
−67
Profit before tax
−79 691
−79 852
−19 927
−15 225
−88 210
Tax
−0
−0
−0
—
—
Net profit
−79 691
−79 852
−19 927
−15 225
−88 210
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
114 228
34 229
15 066
28 170
212 804
Equity
101 644
22 117
12 190
5 840
191 725
Long-term debt
0
0
0
—
—
Short-term debt
12 584
12 112
2 875
22 330
21 079
Total debt
12 584
12 112
2 875
22 330
21 079
Financial ratios
5-year trend
EBITDA-margin
-8812296700.0%
This company
15.8%
Market median
-55774029847% vs market
2021
2025
Soliditetsgrad
90.1%
This company
38.2%
Market median
+136% vs market
2021
2025
Egenkapitalforrentning
-46.0%
This company
18.4%
Market median
-350% vs market
2021
2025
Nettoresultatgrad
-8820980300.0%
This company
8.1%
Market median
-108900991458% vs market
2021
2025
Aktivomsætning
-0.31×
This company
1.12×
Market median
-128% vs market
2021
2025
Gæld/egenkapital
0.11×
This company
0.62×
Market median
+82% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Gesynta Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
